Fiche publication
Date publication
janvier 2017
Journal
Bio-medical materials and engineering
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BENKIRANE-JESSEL Nadia
,
Dr IDOUX-GILLET Ysia
Tous les auteurs :
Offner D, Wagner Q, Idoux-Gillet Y, Gegout H, Ferrandon A, Schwinté P, Musset AM, Benkirane-Jessel N, Keller L
Lien Pubmed
Résumé
The time needed to obtain functional regenerated bone tissue depends on the existence of a reliable vascular support. Current techniques used in clinic, for example after tooth extraction, do not allow regaining or preserving the same bone volume. Our aim is to develop a cellularized active implant of the third generation, equipped with human mesenchymal stem cells to improve the quality of implant vascularization. We seeded a commercialized collagen implant with human mesenchymal stem cells (hMSCs) and then with human umbilical vein endothelial cells (HUVECs). We analyzed the biocompatibility and the behavior of endothelial cells with this implant. We observed a biocompatibility of the active implant, and a re-organization of endothelial cells into clustered networks. This work shows the possibility to develop an implant of the third generation supporting vascularization, improving the medical care of patients.
Mots clés
Animals, Biocompatible Materials, chemistry, Cattle, Collagen, chemistry, Human Umbilical Vein Endothelial Cells, cytology, Humans, Materials Testing, Mesenchymal Stromal Cells, cytology, Neovascularization, Physiologic, Tissue Engineering, methods, Tissue Scaffolds, chemistry
Référence
Biomed Mater Eng. 2017 ;28(s1):S185-S192
